The 2nd Edition: Cellular and Humoral Immunity after COVID-19 Vaccination

Dear Colleagues,

The outbreak of the COVID-19 pandemic at the turn of 2019 and 2020 posed a substantial global challenge. The number of infected people and deaths reached unprecedented levels, paralyzing health services in many countries. Vaccination was the most effective tool of pandemic control. In clinical practice, vaccination produced decreased infections, a milder course of COVID-19, and a reduced mortality rate. One should also remember that the natural course of the pandemic and subsequent mutations of the SARS-CoV-2 weakened the virus and contributed to a milder course of the disease and the gradual extinction of the pandemic. Although many aspects of COVID-19 immunity and vaccine response have already been clarified, there is still a sizable gap between clinicians’ questions and the available explanations. This is especially true given the evolution of SARS-CoV-2 and new emerging variants and requires further research.

The second edition of this Special Issue, entitled "Cellular and Humoral Immunity after COVID-19 Vaccination", will summarize the current state of knowledge. Potential submission topics include (but are not limited to) the following issues:

1. The efficacy and reactogenicity of vaccines against new variants of SARS-CoV-2;
2. The efficacy supplementary doses of classical vaccines against the original Wuhan SARS-COV-2 strain in preventing infections, hospitalizations and death caused by new variants of the virus;
3. Long-term safety of vaccines against SARS-CoV-2;
4. Cellular and humoral response in immunocompetent and immunocompromised population;
5. Differences in the immune response between vaccines;
6. Schemes of vaccination enhancing immune responses in immunocompromised patients;
7. Comparing immune response after vaccination with the natural immunity of convalescents;
8. Vaccines against new variants.

In this Special Issue, original research articles and reviews are welcome. We look forward to your contributions.

Prof. Dr. Leszek Tylicki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• COVID-19
• SARS-CoV-2
• humoral immunity
• cellular immunity
• vaccine
• vaccination

• Cellular and Humoral Immunity after COVID-19 Vaccination in Vaccines (12 articles)